{"id":"liraglutide-monotherapy","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Nausea"},{"rate":"5-15","effect":"Vomiting"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"10-20","effect":"Constipation"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Hypoglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Liraglutide binds to and activates the GLP-1 receptor on pancreatic beta cells, enhancing glucose-dependent insulin secretion. It also inhibits glucagon secretion when blood glucose is elevated and delays gastric emptying, reducing postprandial glucose excursions. These combined effects improve glycemic control in type 2 diabetes.","oneSentence":"Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying in response to elevated blood glucose.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:40.757Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus monotherapy"}]},"trialDetails":[{"nctId":"NCT07301437","phase":"PHASE4","title":"RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.","status":"NOT_YET_RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2026-05-01","conditions":"Overweight and Obese Adults","enrollment":120},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT01541215","phase":"PHASE3","title":"Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-11-13","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":135},{"nctId":"NCT02686177","phase":"PHASE4","title":"Effect of GLP-1 on Angiogenesis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-05-18","conditions":"Type 2 Diabetes","enrollment":50},{"nctId":"NCT03018028","phase":"PHASE3","title":"Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-01-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":243},{"nctId":"NCT02730377","phase":"PHASE4","title":"Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-03-28","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1991},{"nctId":"NCT02292290","phase":"PHASE4","title":"Trial for People With Established Type 2 Diabetes During Ramadan","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2011-04","conditions":"Type 2 Diabetes","enrollment":99},{"nctId":"NCT01234649","phase":"PHASE3","title":"Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)","status":"COMPLETED","sponsor":"Woman's","startDate":"2011-08-11","conditions":"Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome","enrollment":153},{"nctId":"NCT01572740","phase":"PHASE3","title":"Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-04-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":257},{"nctId":"NCT01512108","phase":"PHASE3","title":"Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-01-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":363},{"nctId":"NCT03353948","phase":"PHASE4","title":"The Effect of a Liraglutide on IVF in Obese PCOS","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2014-09-01","conditions":"Polycystic Ovary Syndrome, Obesity, Infertility, Female","enrollment":30},{"nctId":"NCT01296412","phase":"PHASE3","title":"Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-11","conditions":"Diabetes Mellitus, Type 2","enrollment":653},{"nctId":"NCT00318461","phase":"PHASE3","title":"To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1091},{"nctId":"NCT01937598","phase":"PHASE3","title":"Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D","status":"COMPLETED","sponsor":"Michael A. Nauck","startDate":"2013-08","conditions":"Type 2 Diabetes","enrollment":16},{"nctId":"NCT03034941","phase":"PHASE4","title":"Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2014-04","conditions":"Obesity, PCOS","enrollment":35},{"nctId":"NCT01511198","phase":"PHASE2","title":"Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":223},{"nctId":"NCT00318422","phase":"PHASE3","title":"Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1041},{"nctId":"NCT01511172","phase":"PHASE2","title":"Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":145},{"nctId":"NCT01733758","phase":"PHASE3","title":"A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02","conditions":"Diabetes Mellitus, Type 2","enrollment":494},{"nctId":"NCT01558271","phase":"PHASE3","title":"A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-03","conditions":"Type 2 Diabetes Mellitus","enrollment":492}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"liraglutide monotherapy","genericName":"liraglutide monotherapy","companyName":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","companyId":"the-fourth-affiliated-hospital-of-zhejiang-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying in response to elevated blood glucose. Used for Type 2 diabetes mellitus monotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}